Drugs & Targets Xalkori receives FDA approval for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma January 15, 2021Vol.47 No.02
Drugs & Targets Pvsripo receives Orphan Drug Designation from FDA for advanced melanoma treatment January 15, 2021Vol.47 No.02
Drugs & Targets Illumina collaborates with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to advance comprehensive genomic profiling January 15, 2021Vol.47 No.02
Drugs & TargetsFree Tagrisso receives FDA approval as adjuvant therapy for NSCLC with EGFR mutations January 08, 2021Vol.47 No.01
Drugs & TargetsFree Iclusig receives FDA sNDA approval for adult patients with resistant or intolerant chronic-phase CML January 08, 2021Vol.47 No.01
Drugs & TargetsFree Xpovio receives FDA approval for refractory or relapsed multiple myeloma January 08, 2021Vol.47 No.01
Drugs & TargetsFree Orgovyx receives FDA approval for advanced prostate cancer January 08, 2021Vol.47 No.01
Drugs & TargetsFree Margenza receives FDA approval for metastatic HER2-positive breast cancer January 08, 2021Vol.47 No.01
Drugs & TargetsFree CPI-613 receives FDA Fast Track Designation for treatment of AML January 08, 2021Vol.47 No.01
Drugs & TargetsFree EU CHMP issues positive opinion for Keytruda as first-line treatment in adult patients in colorectal cancer indication January 08, 2021Vol.47 No.01
